

ACTION REQUEST

Subject: Subcontract Agreement between the University of Michigan and Immunogenics, LLC

Action Requested: Authorization to enter into Agreement

Preamble:

A statutory conflict of interest situation was identified by the Office of Research and Sponsored Projects while reviewing the Proposal Approval Form which then triggered a review by the Medical School Conflict of Interest Board. A plan for management of the possible risks associated with the conflict of interest was then developed and approved by the Board and agreed to by the parties involved.

This proposed agreement ("Agreement") falls under the State of Michigan Conflict of Interest Statute because Professor David Lubman is an employee of the University of Michigan ("University"), and a partial owner of Immunogenics, LLC. The law permits such an Agreement provided it is disclosed to the Board of Regents ("Regents") of the University of Michigan and approved in advance by a 2/3 vote.

Background:

David Lubman, PhD, a Professor in the Departments of Surgery, Surgery Immunology, and Pathology, is the partial owner of a for-profit company called Immunogenics, LLC (the "Company"). The Company wishes to fund a National Institutes of Health (prime) STTR Phase I project entitled "Multiplexed Detection of Biomarkers in Blood Serum for Early Warning of Pancreatic Cancer" (ORSP #16-PAF01235) in the Department of Surgery under the direction of Dr. David Lubman. The purpose of this project is to measure key biomarker levels in blood serum for stage-1 pancreatic cancer patients using ELISA method.

Agreement Terms:

The terms of the Agreement conform to University policy. The period of performance for the project is approximately nine (9) months. The amount of funding support will not exceed \$70,000. Since research projects are often amended, this agreement includes a provision for changes in time and scope. University procedures for approval of these changes will be followed and additional conflict of interest review will be done as appropriate.

Impact of the Agreement

The Agreement will support an effort by Dr. Lubman to use his expertise and University laboratory, as well as other University resources to measure key biomarker levels in blood serum for stage-1 pancreatic cancer patients using ELISA method, and to obtain further statistical validation for differentiation of key biomarkers in the three designated patient groups.

Recommendations:

This matter has been reviewed and approved by the Medical School Conflict of Interest Board. In light of this disclosure and our finding that the Agreement was negotiated in conformance with standard University practices, I recommend that the Board of Regents approve the University's entering into this Agreement with Immunogenics, LLC.

Respectfully submitted,

A handwritten signature in blue ink, appearing to read "S. Jack Hu".

S. Jack Hu  
Interim Vice President for Research

October 2015